Amylyx Pharmaceuticals Announced Topline Results From PHOENIX Phase 3 Trial Of AMX0035 For Amyotrophic Lateral Sclerosis, The Study Did Not Meet Its Primary Endpoint Nor Was There Statistical Significance Seen In Secondary Endpoints
Amylyx Pharmicals 公布了 PHOENIX 针对肌萎缩性侧索硬化症的 AMX0035 三期试验的主要结果,该研究未达到其主要终点,次要终点也没有统计学意义